Xilio Therapeutics Inc (NASDAQ:XLO) shares, rose in value, with the stock price down by -12.16% to the previous day’s close as strong demand from buyers drove the stock to $1.30.
Actively observing the price movement in the last trading, the stock closed the session at $1.48. Referring to stock’s 52-week performance, its high was $3.67, and the low was $0.49. On the whole, XLO has fluctuated by 78.11% over the past month.
As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.37, which is expected to increase to -$0.36 for fiscal year -$1.75 and then to about -$1.37 by fiscal year 2025. Data indicates that the EPS growth is expected to be 37.10% in 2025, while the next year’s EPS growth is forecast to be 21.70%.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 1 upward and no downward review(s) in last seven days. We see that XLO’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a Hold.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of XLO currently trading nearly 59.95% and 84.15% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 69.08, while the 7-day volatility ratio is showing 38.99% which for the 30-day chart, stands at 19.93%. Furthermore, Xilio Therapeutics Inc (XLO)’s beta value is -0.15, and its average true range (ATR) is 0.22.
A comparison of Xilio Therapeutics Inc (XLO) with its peers suggests the former has fared considerably weaker in the market. XLO showed an intraday change of -12.16% in last session, and over the past year, it shrunk by -58.99%%.
Data on historical trading for Xilio Therapeutics Inc (NASDAQ:XLO) indicates that the trading volumes over the past 10 days have averaged 6.86 million and over the past 3 months, they’ve averaged 1.13 million. According to company’s latest data on outstanding shares, there are 27.61 million shares outstanding.
Nearly 49.70% of Xilio Therapeutics Inc’s shares belong to company insiders and institutional investors own 15.44% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 57630.0 shares as on Mar 15, 2024, resulting in a short ratio of 0.26. According to the data, the short interest in Xilio Therapeutics Inc (XLO) stood at 0.21% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 33750.0. The stock has risen by 136.36% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the XLO stock heading into the next quarter.
